The study to validate a new, low-cost genome screening procedure on embryos used for in-vitro fertilization produced its first healthy baby, the research team announced last week. "If further randomized trials confirm this, we could reach a point where there is a very strong economic argument that this should be offered very widely -- perhaps to the majority of IVF patients," said the study's leader Dagan Wells of the University of Oxford.

Full Story:

Related Summaries